INNOVATIVE PARTNERSHIP FOR ACTION AGAINST CANCER (iPAAC) Official - - PowerPoint PPT Presentation

INNOVATIVE PARTNERSHIP FOR ACTION AGAINST CANCER (iPAAC)

Official iPAAC Joint Action presentation

GENERAL INFORMATION

• The Innovative Partnership for Action Against Cancer (iPAAC) Joint Action, which

has been selected for funding under the Third Health Programme (2014–2020), brings together 44 partners from 24 European countries.

• It aims to build upon the outcomes of previous EPAAC and CANCON Joint Actions

and is coordinated by the National Institute of Public Health of the Republic of Slovenia (NIJZ).

• The iPAAC Joint Action has officially

started on 1st April 2018 and will last for three years.

Official iPAAC Joint Action presentation

iPAAC BUDGET: 5.625.000 EUR 4.500.000 EUR co-funding by EC (80 %)

iPAAC STRUCTURE

Innovative Partnership for Action Against Cancer (iPAAC) is the third consecutive Joint Action dedicated to cancer control. iPAAC WORK PACKAGES: WP 1 – Coordination

National Institute of Public Health of Slovenia (NIJZ)

WP 2 – Dissemination

Institute of Health Information and Statistics of the Czech Republic (UZIS)

WP 3 – Evaluation

Croatian National Institute of Public Health (HZJZ)

WP 4 – Integration in National Policies and Sustainability

Belgian Cancer Centre, Sciensano (SC)

Official iPAAC Joint Action presentation

iPAAC STRUCTURE

WP 5 – Prevention and Screening

Cancer Society of Finland (CSF)

WP 6 – Genomics in Cancer Control and Care

Belgian Cancer Centre, Sciensano (SC)

WP 7 – Cancer Information and Registration

Italian National Institute of Public Health (ISS)

WP 8 – Challenges in Cancer Care

Catalan Institute of Oncology (ICO)

WP 9 – Innovative Therapies in Cancer

French National Institute of Cancer (INCa)

WP 10 – Governance of Integrated and Comprehensive Cancer Care

German Federal Ministry of Health and German Cancer Society (DKG)

Official iPAAC Joint Action presentation

iPAAC PARTNER COUNTRIES

Official iPAAC Joint Action presentation

iPAAC PARTNERS – COMPETENT AUTHORITIES

• 1. (Coordinator)

National Institute of Public Health of the Republic of Slovenia (NIJZ) Slovenia 2. Sciensano (SC) Belgium 3. National Center of Public Health and Analyses (NCPHA) Bulgaria 4. Croatian Institute of Public Health (CIPH) Croatia 5. Ministry of Health of the Republic of Cyprus (MOH) Cyprus 6. Institute of Health Information and Statistics of the Czech Republic (UZIS) Czech Republic 7. National Institute for Health and Welfare (THL) Finland 8. French National Cancer Institute (INCA) France 9. Federal Ministry of Health (BMG) Germany 10. 7th Health Region of Crete (7 HRC) Greece 11. National Institute of Oncology (OOI) Hungary 12. Department of Health (DoH) Ireland

Official iPAAC Joint Action presentation

iPAAC PARTNERS – COMPETENT AUTHORITIES

13. National Institute of Health (ISS) Italy 14. Ministry of Health of the Republic of Lithuania (SAM) Lithuania 15. Ministry for Health – Government of Malta (MFH) Malta 16. Institute of Oncology of the Republic of Moldova (IMSP IO) Moldova 17. National Institute for Public Health and The Environment (RIVM) Netherlands 18. Oslo University Hospital (OUS) Norway 19. National Institute of Public Health – National Institute of Hygiene (NIZP – PZH) Poland 20. Ministry of Health of Portugal (MS) Portugal 21. National Institute of Public Health (INSP) Romania 22. Institute of Public Health of Serbia “Dr Milan Jovanović Batut” (IPHS) Serbia 23. Biomedical Research Center of the Slovak Academy of Sciences (BMC SAS) Slovakia 24. Catalan Institute of Oncology (ICO) Spain

Official iPAAC Joint Action presentation

iPAAC PARTNERS – AFFILIATED ENTITIES

1. Institute of Oncology Ljubljana (OIL) Slovenia 2. Masaryk University (MUNI) Czech Republic 3. Cancer Society of Finland (CSF) Finland 4. German Cancer Research Center (DKZF) Germany 5. German Cancer Society (DKG) Germany 6. Technical University Dresden (TU Dresden)

• Chair of Information Systems, esp. Systems Development
• Centre for Evidence-based Healthcare

Germany 7. University Medicine Köln (UK Köln) Germany 8. Italian Ministry of Health (MoH) Italy 9. Vilnius University Hospital Santaros Klinikos (VUHSK) Lithuania 10. “Marius Nasta” Pneumophtisiology Institute (IPMN) Romania 11. Oncology Institute “Prof. Dr. Ion Chiricuţă” (IOCN) Romania

Official iPAAC Joint Action presentation

iPAAC PARTNERS – AFFILIATED ENTITIES

12. Emergency Clinical County Hospital Craiova (CCHC) Romania 13. Clinical Centre of Kragujevac (CCK) Serbia 14. Faculty of Medicine, University of Belgrade (UBEO) Serbia 15. Institute for Oncology and Radiology of Serbia (IORS) Serbia 16. Public Health Institute Niš (IPHN) Serbia 17. Institute of Public Health of Vojvodina (IPHV) Serbia 18. Oncology Institute of Vojvodina (IOV) Serbia 19. Provincial Secretariat for Health Care (APV) Serbia 20. Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO) Spain

Official iPAAC Joint Action presentation

TARGET GROUP

The primary target group of the iPAAC Joint Action will be policymakers at the EU level and decision makers at the national, regional and local level. All of the innovative actions covered by the JA work packages will be assessed on the basis of sustainability and integration into national policies.

Official iPAAC Joint Action presentation

GENERAL OBJECTIVE OF THE iPAAC JOINT ACTION

The general objective of the iPAAC Joint Action (JA) is to develop innovative approaches to advances in cancer control. The development of innovative approaches to cancer control will be supplemented by a Roadmap on Implementation and Sustainability of Cancer Control Actions, which will support Member States in implementation of iPAAC and CANCON recommendations. Roadmap on Implementation and Sustainability of Cancer Control Actions is the key deliverable of the Joint Action.

Official iPAAC Joint Action presentation

SPECIFIC OBJECTIVES

1. To develop and produce the Roadmap on Implementation and Sustainability of Cancer Control Actions. 2. To reinforce prevention of cancer through further development of the European Code Against Cancer and population-based screening programmes. 3. To develop a comprehensive approach to the use of genomics in cancer control and care. 4. To pilot the integration of population-based cancer registry datasets with clinical and administrative data to derive key indicators on cancer care pathway and health-related costs in selected European countries or regions and to deliver informative epidemiological indicators on cancer prevalence by country in Europe.

Official iPAAC Joint Action presentation

SPECIFIC OBJECTIVES

Official iPAAC Joint Action presentation

5. To define strategies to improve the quality of cancer care by optimising the use

• f healthcare resources and promoting realistic and evidence-based responses

to existing needs. 6. To map recommendations and best practice guidelines for specific immunotherapies, to anticipate and predict impact

• f

new specific immunotherapies before their marketed authorisation and to follow specific immunotherapies after their marketed authorisation. 7. To develop practical instruments to support Member States in successful governance

• f

cancer care, ensuring standardised, integrated and comprehensive oncological care that is tumour-specific and delivers all- encompassing high-quality care to all patients.

iPAAC OUTCOMES

Official iPAAC Joint Action presentation

Support for Member States in implementing recommendations from the CANCON Joint Action at national, regional and local levels. Reinforcing of cancer prevention through a review of current recommendations for cancer screening and a sound assessment of the potential that might exist for the introduction of possible new screening programmes, through a critical evaluation and assessment of the impact the activities in the field of genomics may have on improving cancer control both at the population level and through assessment of the implementation and potential modifications of the European Code Against Cancer.

iPAAC OUTCOMES

Official iPAAC Joint Action presentation

• Providing better efficacy for dealing with neglected cancers through

development of new key indicators to assess clinical patient pathways and health care related costs of cancer and its interventions, particularly in the case of pancreatic cancer.

• Supporting the introduction of immunotherapies into clinical practice

through a comprehensive assessment of immunotherapies and their effectiveness.

• Evaluation of cancer care in European countries through an

assessment of quality indicators.

• Support for policymakers in the field of governance, including pilot

comprehensive cancer care networks and an updated analysis of national cancer control programmes in the EU.

CONTACTS

Official iPAAC Joint Action presentation

Project management team National Institute of Public Health of the Republic of Slovenia ipaac@nijz.si Dissemination team Institute of Health Information and Statistics of the Czech Republic ipaac-pr@uzis.cz Official website of the iPAAC JA: www.ipaac.eu